All In Biotech

Drug Trial Radar · NCT03375502

A Study of MG1111 in Healthy Children

A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children

Last checked: Nov 19, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

814

Actual

Start

Nov 26, 2016

Primary completion

Jan 29, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
Green Cross CorporationIndustry
Sponsor type
Industry
First posted
Dec 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 12 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator

Conditions

  • Healthy Children

Interventions

  • Varicella VaccineDrug

    The subject will receive investigational product or comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieved seroconversionTime frame: 42 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The catholic university of Korea, Seoul st. mary's hospital

    Banpo-dong, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.